This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines, highlighting the stories and stocks that should be on all investors' radars. Market Checkup gives a full examination of the recent regulatory action around a new super fish-oil drug and looks at a yet another biotech putting itself up for sale.
In this video, health-care analysts David Williamson and Max Macaluso discuss the FDA's accepting a new drug application for Epanova. AstraZeneca recently spent more than $400 million acquiring the rights to the fish oil-based drug and has big plans for it. Watch and find out about Epanova's competitors, why recent studies may work against it, and what AstraZeneca has up its sleeve that makes this drug so important to the big pharma.
Prescription for dividends
One of the best parts of owning Big Pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
Follow David on Twitter: @MotleyDavid.